Searched for
NOVARTIS MALARIA DRUG
Anthropic appoints Indian-origin Novartis CEO Vas Narasimhan to its boardAnthropic’s Long-Term Benefit Trust is an independent governance body, designed to insulate key decisions as it scales its frontier AI syst...- The first drug to treat infants sick with malaria is approved by Swiss authoritySwissmedic has approved Coartem Baby, a malaria medicine specifically formulated for infants weighing 2 to 5 kilograms. This marks the firs...
- Novartis gets approval for first malaria drug for babies and childrenNovartis has secured approval in Switzerland for Coartem Baby, a groundbreaking medication designed to treat malaria in babies and young ch...
- WHO's Solidarity clinical trials: India to start trials of two new drugs to treat Covid-19India is among the 52 countries taking part in WHO's Solidarity PLUS trial. This collaboration for Covid-19 research is also studying the e...
- How Trump's hydroxychloroquine push became a boon for Ipca LaboratoriesThe US is still relying on Indian firms to import HCQ even after the drug fell out of favor as a Covid treatment.
- EU governments ban malaria drug for COVID-19, trial paused as safety fears growThe moves by France, Italy and Belgium followed a World Health Organization decision on Monday to pause a large trial of hydroxychloroquine...
- Novartis, Roche lift European shares as earnings jitters remainThe pan-European STOXX 600 index gained 0.2 per cent, after ending Friday with its biggest two-week percentage increase since 2015.
- Novartis, U.S. regulators agree to malaria drug hydroxychloroquine trial against COVID-19Novartis has reached an agreement with U.S. regulators to hold a randomized trial of generic malaria drug hydroxychloroquine against COVID-...
- Novartis scraps sale of assets including COVID-19 hopeful to India's AurobindoNovartis AG on Thursday scrapped the $1 billion sale of U.S. generic pill and skin drug assets to India's Aurobindo Pharma Ltd as regulator...
- Malaria medicine 'Hydroxychloroquine' being administered to 1,100 COVID19 patients in New York: US President Donald TrumpAn inexpensive drug widely used since 1955 to treat malaria, Hydroxychloroquine is considered to have relatively harmless side effects. It ...
- Novartis CEO says Malaria drug is biggest hope against coronavirus - SonntagsZeitungOther companies including Bayer and Teva have also agreed to donate hydroxychloroquine or similar drugs, while Gilead Sciences is testing i...
- There’s an explosion of data & digital opportunities in Indian healthcare: Vasant Narasimhan, CEO, NovartisOur chief focus for future investments will be: One on increasing our R&D footprint here over time. Second is data and digital.
- US watch list may hit affordable drug businessIndia remains on Priority Watch List, and continues to be singled out for what the USTR considers to be inadequate protection of intellectu...
- Cipla asks government to revoke five patents held by NovartisCipla, India’s fifthlargest drugmaker by revenue, has asked the government to revoke five patents that Novartis holds on respiratory drug O...
- Private sector deserts war on Tuberculosis, funding down 33% since 2011Multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).
- New drug target to fight malaria identifiedThe disease is caused by Plasmodium parasites, which are transmitted to humans by the infectious bite of an Anopheles mosquito.
- India must support R&D for neglected diseasesIndia has been neglecting funding research of diseases such as tuberculosis, malaria, sleeping sickness while funds are poured into honing ...
- MNC, domestic pharma cos lock horns over patents in IndiaMNC durgmakers on Wednesday hit back at their domestic counterparts over frivolous patent issue and said even the local firms are engaged i...
- NPPA revision of 174 drug prices may lead to costlier medicinesInsulin brands, steroids and painkillers may become more expensive once NPPA revises prices of more than 170 medicines, in some cases by as...
- Novartis cuts cost of malaria drug Coartem by 20%Swiss drug maker Novartis says it is lowering the public-sector price of its antimalarial drug Coartem by 20 per cent.
Load More
